Preliminary analysis of azoxymethane-induced colon tumorigenesis in mouse aggregation chimeras.
Inbred mice exhibit differential susceptibility to colon carcinogens. The following study addresses the possibility that differences are intrinsic to colonic mucosa (cell autonomous) or are mediated by extracolonic systemic factors (e.g. liver activation of carcinogens). Our approach was to construct mouse aggregation chimeras, mice whose tissues are a mosaic of cells derived from two parental genotypes, from a susceptible (SWR) and a resistant (DBA/2) strain. Forty-five embryo aggregations yielded 11 viable pups, four of which were chimeric by coat color. Six-week-old SWR<-->BA/2 chimeras were injected i.p. with azoxymethane (AOM) once a week for 8 weeks (5 and 7.5 mg/kg body wt for 2 weeks followed by 10 mg/kg for 6 weeks) and tumor incidence in distal colon was evaluated 15 weeks after the last injection. Additional groups of parental mice received the same treatment. In the parental SWR treatment group, 1.7 +/- 0.82 tumors/colon were found. No tumors were observed in AOM-treated DBA/2 mice. In SWR<-->DBA/2 chimeras exposed to AOM, 2.8 +/- 2.1 tumors/colon were found. Tumor lineage was examined in paraffin sections stained with Dolichos biflorus agglutinin-peroxidase, a cell surface specific marker that stains intestinal endothelial cells of SWR and epithelial cells of DBA/2. Cellular lineage of tumors was further evaluated by microsatellite analysis of DNA isolated by microdissection. There was no significant difference in tumor incidence between SWR parental and chimera treatment groups. Histochemical analysis of tumor tissue in chimeras suggested that most tumors were derived from SWR. However, subsequent genetic analysis of tumors indicated mixed parental composition. These preliminary studies suggest that DBA/2 resistance mechanisms are not sufficient to protect adjacent SWR-derived epithelium from the tumorigenic effects of AOM.
Wang
Q S
QS
Department of Pharmaceutical Sciences, University of Connecticut, Storrs 06269-2092, USA.
Walsh
A
A
Goldsby
J S
JS
Papanikolaou
A
A
Bolt
A B
AB
Rosenberg
D W
DW
D000818:Animals; D001397:Azoxymethane / Q000008:administration & dosage / Q000633:toxicity*; D015415:Biomarkers; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D019070:Cell Lineage; D002678:Chimera; D002999:Clone Cells / Q000473:pathology; D003106:Colon / Q000187:drug effects* / Q000473:pathology; D003110:Colonic Neoplasms / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005838:Genotype; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains / Q000235:genetics*; D018895:Microsatellite Repeats
D015415:Biomarkers; D002273:Carcinogens; D004273:DNA, Neoplasm; D001397:Azoxymethane